Healthtech funding in H2 2012
European Healthtech startup funding raised during H2 2012.
In H2 2012, 37 European Healthtech companies closed 38 funding rounds and raised €295M in equity funding (excluding debt and grants), up 32.1% versus H2 2011. Switzerland led by capital raised, and Advent Venture Partners was the most active investor. Data as of 6 Nov 2026.
Equity funding
€295M
+32.1% vs H2 2011 · excl. debt & grants
Funding rounds
38
+52.0% vs H2 2011
Companies
37
Top country
Switzerland
Rank among sectors
#2
12.1% of sector funding
Top-10 round share
86.3%
of disclosed capital
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H2 2012 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €54M | 8 |
| Sep | €115M | 5 |
| Oct | €16M | 5 |
| Nov | €60M | 9 |
| Dec | €58M | 11 |
Top countries
by € raisedHealthtech — top countries by capital, H2 2012 — interactive chart.
Data table
| Healthtech — top countries by capital, H2 2012 | |
|---|---|
| Switzerland | €92M |
| UK | €86M |
| Germany | €81M |
| Israel | €21M |
| France | €14M |
| Spain | €4.7M |
| Russia | €1.6M |
| Estonia | €1.4M |
Stage mix
by € raisedHealthtech — stage mix, H2 2012 — interactive chart.
Data table
| Healthtech — stage mix, H2 2012 | |
|---|---|
| Series D+ | €126M |
| Series C | €62M |
| Other | €32M |
| Growth/Late | €27M |
| Early VC | €21M |
| Series A | €14M |
| Grant | €7.4M |
| Series B | €6.6M |
| Seed | €5.6M |
Exits & M&A
1 Buyout1 exit.
Top deals
largest disclosed rounds in H2 2012| Company | Stage | Date | Amount |
|---|---|---|---|
| CureVac | Series D+ | Sep 2012 | €80M |
| Biocartis | Series D+ | Dec 2012 | €35M |
| Endosense | Series C | Nov 2012 | €31M |
| F2G | Growth/Late | Sep 2012 | €27M |
| Cell Medica | Other | Jul 2012 | €24M |
| GenKyoTex | Series C | Jul 2012 | €21M |
| NeRRe Therapeutics | Series A | Dec 2012 | €14M |
| EarlySense | Series D+ | Nov 2012 | €12M |
| GlySure | Series C | Nov 2012 | €10M |
| CartiHeal | Early VC | Jul 2012 | €7.9M |
| THERAVECTYS | Other | Sep 2012 | €7.5M |
| Biom'Up | Early VC | Oct 2012 | €6.8M |
| NovImmune | Grant | Oct 2012 | €6.0M |
| Cardiosonic | Series B | Dec 2012 | €4.7M |
| Qinec | Series B | Nov 2012 | €1.9M |
Top investors
most active in H2 2012, by deal count- Advent Venture Partners2 deals
- Amadeus Capital Partners2 deals
- The North West Fund2 deals
- Astellas Venture Management1 deals
- Aurora Venture Capital1 deals
- Bethnal Green Ventures1 deals
- Clydesdale Bank PLC1 deals
- Delta Partners1 deals
- GIMV1 deals
- High-Tech Gründerfonds (HTGF)1 deals